Revive Therapeutics Extends Proposed Private Placement

09/05/2025 – 07:50 PM

TORONTO, Sept. 05, 2025 – Revive Therapeutics Ltd. (OTCQB: RVVTF), a specialty life sciences company focusing on novel therapeutics for unmet medical needs, announced an extension to its previously disclosed private placement offering. The company intends to raise up to $650,000 by issuing up to 30,952,381 units priced at $0.021 each. This move comes as Revive seeks to bolster its working capital amid an evolving biotechnology landscape.

According to the official release, each unit comprises one common share of Revive Therapeutics and one common share purchase warrant. The warrants allow the holder to purchase one common share at an exercise price of $0.05, valid for 36 months post-closing. The unit pricing aligns with the 20-day Volume Weighted Average Price (VWAP) of the shares traded on the Canadian Securities Exchange (CSE) when the company initially secured price protection.

The company successfully completed the first tranche of the private placement in early August 2025, generating gross proceeds of $60,900 through the issuance of 2,900,000 units at $0.021 per unit. Consequently, Revive has the capacity to issue an additional $589,000 worth of units through this private placement.

Revive Therapeutics intends to allocate the gross proceeds from the private placement to augment its working capital and settle specific trade payables. The company has structured the offering to potentially close in multiple tranches, providing flexibility in its funding approach.

The closing of each private placement tranche is contingent upon standard closing conditions. The company aims to close the offering as expeditiously as possible. All securities issued under this private placement will be subject to a statutory hold period of four months and one day from the date of issuance, a standard measure to prevent immediate resale and potential market volatility.

Financial Analysis & Strategic Implications:
Revive Therapeutics’ decision to extend its private placement comes at a pivotal time for many biotech companies facing challenging capital markets. While the initial tranche indicates investor interest, the low unit price of $0.021 raises concerns about the company’s valuation and perceived financial health. The potential dilution from the additional 30.95 million shares, coupled with the warrant exercise option, could further impact existing shareholders.

However, the flexibility of closing the placement in tranches offers Revive the advantage of adapting to market conditions. The $0.05 warrant exercise price could provide the company with additional capital in the future, assuming the stock price appreciates sufficiently to incentivize warrant holders. Investors should carefully consider the dilution risks and the potential upside associated with Revive’s therapeutic pipeline when evaluating this offering.

About Revive Therapeutics Ltd.

Revive Therapeutics is a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs. Revive strategically prioritizes its drug development pipeline to leverage FDA regulatory incentives like Emergency Use Authorization, Orphan Drug, Fast Track, and Breakthrough Therapy designations, positioning for rapid advancement and market entry. Currently, our efforts are concentrated on unlocking the vast potential of Bucillamine for infectious diseases and medical countermeasures, including the pioneering treatment of nerve agent exposure. Furthermore, Revive is vigorously advancing our Psilocybin and molecular hydrogen therapeutic programs, exploring new frontiers in medical science. For more information, visit www.ReviveThera.com.

Neither the Canadian Securities Exchange nor its Regulation Services Provider has reviewed or accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statement

This press release contains ‘forward-looking information’ within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “may”, “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Revive’s current belief or assumptions as to the outcome and timing of such future events. Forward looking information in this press release includes information with respect to the Company’s cannabinoids, psychedelics and infectious diseases programs. Forward-looking information is based on reasonable assumptions that have been made by Revive at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Revive is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. Reference is made to the risk factors disclosed under the heading “Risk Factors” in the Company’s management’s discussion and analysis for the three and nine months ended March 31, 2025 (“MD&A”), dated May 29, 2025, which is available on the Company’s profile at www.sedarplus.ca.